Business
China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin
TAIZHOU, China, Jan. 14, 2022 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical
About this update from China Sxt Pharmaceuticals, Inc.
[{"type":"text","content":"TAIZHOU, China, Jan. 14, 2022 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (\"China SXT\" or the \"Company\"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (\"TCMPs\"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (\"TCMHS\") announced today that it develops and commercializes the Kuihuapan After-Soaking-Oral TCMP and Zhudanfen Directly-Oral TCMP products. The Kuihuapan products are produced according to the four processing specifications of Chinese Pharmacopoeia (2020 Edition) No. 34 of China Heilongjiang food and Drug Administration Note Letter [2020], and have the functions of clearing heat, calming liver, dredging collaterals and relieving pain. Its indications include dizziness, tinnitus, joint pain, hyperuricemia, gout, hypertension and other symptoms. The Zhudanfen products are produced according to the processing specifications of Chinese Pharmacopoeia (2020 Edition), it has the functions of clearing heat and moistening dryness, relieving cough and asthma, and detoxifying, and is suitable for sudden cough, asthma, fever, thirst, red eyes, throat obstruction, jaundice, diarrhea, dysentery, constipation, sores, carbuncle, swelling and poison. Zhudanfen is also listed in the National Medical Insurance Catalogue (No. 697 of the National Medical Insurance Catalogue). We expect that the annual output of both Kuihuapan and Zhudanfen to reach 300,000 bottles, and achieve the sales of about RMB 5 million during the fiscal year ending March 31, 2023. \nIn addition, although the GMP compliance inspection conducted by Jiangsu Province Medical Products Administration (JSMPA) for the Company's new lyophilization production facilities in June 18, 2021 delayed the production cycle and the production capacity decreased consequently, compared with the same period. JSMPA completed its inspection in June 20, 2021. As of December 31, 2021, there are 12 batches of Luxuejin Directly-Oral TCMP products produced by lyophilization process. The Company has consumed 2.08 tons of fresh bloods of Cuerus Nippon as the raw materials, and the total amount of Luxuejin after freeze-drying is 316.92 kilogram, which is expected to achieve the sales of...